<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>8
<FILENAME>t1402271_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: Black"><B>Exhibit 10.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>CONFIDENTIAL TREATMENT REQUESTED
UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>[*] INDICATES OMITTED MATERIAL THAT
IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY
WITH THE COMMISSION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>License Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><I>between</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>Mallinckrodt
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><I>and</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>BioSynthema Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>TABLE OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="color: Black"><B>Article 1</B></FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Definitions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>4</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 2 </B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">License</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>11</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 3 </B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Development and Commercialization</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>11</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 4</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Manufacture</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>12</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 5 </B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Consideration</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>12</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 6</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Commercialization Option</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>14</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 7</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Intellectual Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>14</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 8</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Representations and Warranties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>17</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 9</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Confidentiality</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>19</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 10 </B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Announcement and Publicity</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>20</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 11</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Term and Termination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>20</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 12 </B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Indemnification and Insurance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>23</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 13</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Information on Clinical Safety and Epidemiology</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>25</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 14</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Governing Law and Jurisdiction</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>25</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Article 15</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20.15pt; text-align: justify"><FONT STYLE="color: Black">Miscellaneous Provisions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: Black"><B>25</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>License Agreement</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">BioSynthema
Inc. / Mallinckrodt Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">This License Agreement
dated the 10<SUP>th</SUP> day of October, 2007 (the &ldquo;<B>Effective Date</B>&rdquo;), is entered into by and between Mallinckrodt
Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal offices at 675 McDonnell
Blvd., Hazelwood, MO 63042 (referred to as &ldquo;<B>Mallinckrodt</B>&rdquo;), and BioSynthema Inc., a corporation organized and
existing under the laws of Missouri, with an office at 4041 Forest Park Avenue, Saint Louis, MO 63108, and its Affiliates (BioSynthema
Inc. and its Affiliates are hereafter referred to as &ldquo;<B>BI</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase; color: Black"><B>INTRODUCTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>WHEREAS</B>,
BI has entered into an agreement with Dr. [*], referred to as the [*] License Agreement (as defined in Article 1) to obtain certain
rights in and to inventions relating to radiolabeled somatostatin analogues covered in the Generic Patents (as defined in Article
1);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>WHEREAS</B>,
BI has entered into an agreement with the Erasmus Hospital Medical Centre (hereinafter &ldquo;<B>Erasmus</B>&rdquo;) in Rotterdam,
The Netherlands, referred to as the Erasmus License Agreement (as defined in Article 1) providing for the transfer of certain
clinical data to BI;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>WHEREAS</B>,
BI has accepted delivery of and has certain exclusive rights to the commercial use of clinical data relevant to the Product (as
defined in Article 1) pursuant to the Erasmus License Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>WHEREAS</B>,
Mallinckrodt owns certain rights to the Mallinckrodt Patents (as defined in Article 1);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>WHEREAS</B>,
BI has, prior to the Effective Date, performed Development (as defined in Article 1) work on the Product in an effort toward ultimately
obtaining Marketing Authorization (as defined in Article 1) for the Product; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>WHEREAS</B>,
BI wishes to obtain and Mallinckrodt agrees to convey certain licenses to the Mallinckrodt Patents, for the purpose of permitting
BI to Develop, manufacture and Commercialize the Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>NOW, THEREFORE</B>,
in consideration of the mutual promises, covenants and agreements hereinafter set forth, the sufficiency of which is hereby acknowledged,
the Parties to this Agreement mutually agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-style: normal; color: Black"><B>ARTICLE
1</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-style: normal; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-style: normal; color: Black"><B>DEFINITIONS</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-style: normal; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">For purposes of
this Agreement the terms defined in this Article shall have the meanings specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="color: Black"><B>1.1</B></FONT></TD>
    <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Accounting Standards&rdquo;</B> shall mean
    GAAP (Generally Accepted Accounting Principles), consistently applied by the respective Party so utilizing such Accounting
    Standards.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.2</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Affiliate&rdquo;</B> shall mean any entity that directly
    or indirectly controls or is controlled by or is under common control with a Party to this Agreement.&nbsp;&nbsp;For purposes
    of this definition, &ldquo;control&rdquo; or &ldquo;controlled&rdquo; means ownership directly or through one or more Affiliates,
    of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation,
    or fifty percent (50%) or more of the equity interest in the case of any other type of legal entity, status as a general partner
    in any partnership, or any other arrangement whereby a Party controls or has the right to control the board of directors or
    equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies
    of a corporation or other entity.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.3</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Agreement&rdquo;</B> shall mean this License Agreement
    together with all exhibits, schedules, and appendices attached to this Agreement, all as respectively amended, modified or
    supplemented by the Parties in accordance with the terms of this Agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.4</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&ldquo;<B>Applicable Laws</B>&rdquo; shall mean all laws, regulations,
    ordinances, rules or standards applicable to the conduct, performance or obligations of either Party hereunder and imposed
    by a governmental, quasi-governmental authority or Regulatory Authority having jurisdiction in the respective portion of the
    Territory, including by way of illustration and not limitation, the U.S. Food, Drug and Cosmetic Act and the Good Manufacturing
    Practices promulgated by FDA or other Regulatory Authorities.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.5</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;BI Early Termination License&rdquo; </B>shall have the
    meaning as set forth in Section 11.4(c).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.6</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;BI Intellectual Property&rdquo;</B> shall mean BI&rsquo;s
    rights (only to the extent they relate to the Product, the Product Components and the Compound) in and to: (1) the Generic
    Patents; (2) any patents licensed or otherwise acquired from a Third Party (including those listed on <B><U>Exhibit 2</U></B>)
    necessary or useful in the Development, manufacture or Commercialization of the Product; (3) the Erasmus clinical patient
    data as granted under the Erasmus License Agreement as of the Effective Date; (4) other clinical patient data from medical
    facilities and other non-clinical data under any Other Data Agreements; (5) any BI New Intellectual Property; (6) any BI Know-How;
    and (7) any intellectual property rights licensed or otherwise acquired from any Third Party which include the right to sublicense
    to Mallinckrodt or its Affiliates as set out in <B><U>Exhibit 2</U></B>.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.7</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;BI Know-How&rdquo;</B> shall mean any proprietary or
    non-proprietary information only to the</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="color: Black">extent related to the Product, the Product Components
    and the Compound including, but not limited to research, development, manufacture and production methods and processes, use,
    inventions, discoveries, formulation, specifications (including raw material, component and product specifications), processes,
    trade secrets, expertise, developments and regulatory information Controlled by BI, whether or not protected under patent,
    trademark, copyright or other legal principles, to which BI has rights.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.8</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;BioSynthema License Rights&rdquo; </B>shall have the
    meaning as set forth in Section 2.1 below.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.9</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;BI New Intellectual Property&rdquo;</B> shall mean: (1)
    any BI Intellectual Property, (2) any BI Know-How, (3) any improvements, enhancements, new discoveries, inventions, applications
    and further know-how conceived, made or acquired by BI and related to the Product, the Product Components and Compound, its
    formulation or the manufacture thereof, (4) any BI rights in the clinical patient data under the Erasmus License Agreement,
    (5) any BI rights to any data arising under the Other Data Agreements and (6) any BI interests in any co-owned intellectual
    property right pertaining to the Product only to the extent that any of the foregoing arises from the Development and/or the
    manufacture of the Product, the Product Components and the Compound from and after the Effective Date hereof. BI New Intellectual
    Property shall include any and all intellectual property rights in the foregoing, including all patents and trademarks, including
    domain names that BI uses in relation to the Compound, the Product Components and/or Product.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.10</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Calendar Quarter&rdquo;</B> shall mean any period of
    three consecutive calendar months during a Calendar Year commencing with the first day of any January, April, July or October.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.11</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Calendar Year&rdquo;</B> shall mean the calendar year,
    starting on January 1 and ending on December 31, in which the first First Commercial Sale of the Product occurs and each successive
    calendar year.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.12</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&ldquo;<B>Combination Product</B>&rdquo; shall mean the Product
    when sold in a finished dosage form containing the Product in combination with one or more other active ingredients.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.13</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Commercialization&rdquo; </B>or<B> &ldquo;Commercialize&rdquo;
    </B>shall mean all activities conducted by a Party either directly, by its Affiliates or through a Third Party and directed
    to marketing, promoting, distributing, importing, exporting, offering for sale or selling a Product in the Field, which may
    include pre-launch market preparation, whether undertaken by a Party alone or with a partner or a Sublicensee. When used as
    a verb, &ldquo;Commercialize&rdquo; means to engage in Commercialization.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.14</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&ldquo;<B>Commercialization Agreement</B>&rdquo; shall have the
    meaning as set forth in Section 6.2(c).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.15</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Commercialization Exercise&rdquo; </B>shall have the
    meaning as set forth in Section 6.2.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.16</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Commercialization Option &rdquo; </B>shall have the meaning
    as set forth in Section 6.1.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="color: Black"><B>1.17</B></FONT></TD>
    <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Commercially Reasonable Effort&rdquo;</B>
    shall mean reasonable efforts and resources customarily used in the nuclear medicine pharmaceutical industry in the United
    States for radiopharmaceutical oncology products with equivalent sales potential to the Product.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.18</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Compound&rdquo;</B> shall mean the somatostatin peptide
    analogue, DOTA&ordm;-Tyr&sup3;-octreotate, as shown in Exhibit 3.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.19</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Confidential Information&rdquo;</B> shall mean and include
    any and all know-how, data and information, not in the public domain, including without limitation information relating to
    the Compound, the Product Component and/or the Product, or the business, marketing, research and development activities, results
    of clinical trials, regulatory proceedings, finances, contractual relationships and operations of the Parties or their Affiliates.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.20</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Controlled&rdquo; or &ldquo;Controls&rdquo;,</B> when
    used in reference to intellectual property, shall mean the legal authority or right of a Party hereto (or any of its Affiliates)
    to make, have made, use, sell, or offer for sale Compound, the Product Components and/or the Product, or to grant a license
    or sub-license of intellectual property rights to another party or to otherwise disclose proprietary or trade secret information
    to such other Party, without: (i) breaching the terms of any agreement with a Third Party; (ii) infringing upon the intellectual
    property rights of a Third Party; or (iii) misappropriating the proprietary or trade secret information of a Third Party.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.21</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Damages&rdquo; </B>shall mean any and all losses, costs,
    claims, liabilities, fines, penalties, damages, expenses, court costs, interest, and reasonable fees of counsel, consultants,
    and expert witnesses, but shall not include consequential damages or lost profits of a Party, its Affiliates or its Sublicensees
    or subcontractors.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.22</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Develop&rdquo; or &ldquo;Development&rdquo;</B> shall
    mean all activities conducted by BI, either directly or through a Sublicensee, as are necessary or useful toward successful
    application for Marketing Authorization.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.23</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Development Costs&rdquo;</B> shall mean all costs and
    expenses as solely determined by BI and incurred by BI in connection with the Development of the Product.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.24</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Dollars&rdquo;</B> or <B>&ldquo;USD&rdquo;</B> shall
    mean the lawful currency of the United States of America.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.25</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Effective Date&rdquo;</B> shall mean the date provided
    in the Preamble to this Agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.26</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;EMEA&rdquo; </B>shall mean the European Medicines Evaluation
    Agency or any successor agency responsible for review and approval of marketing applications for human drugs or diagnostics
    in the EU.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.27</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Erasmus License Agreement&rdquo; </B>means the agreement
    between Erasmus Hospital and BI which grants to BI rights in clinical data on approximately five hundred (500) patients treated
    with the Product, including data on safety, efficacy and outcome, for inclusion in</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="color: Black">a New Drug Application for submission to Regulatory
    Authorities to obtain Marketing Authorization for the Commercialization of the Product.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.28</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;EU&rdquo; </B>shall mean the European Union, as it may
    be constituted from time to time.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.29</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;FDA&rdquo;</B> shall mean the U.S. Food and Drug Administration
    or its successor agency responsible for review and approval of marketing applications for human drugs or diagnostics in the
    US.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.30</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Field&rdquo;</B> shall mean human oncology.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.31</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;First Commercial Sale&rdquo;</B> shall mean the first
    arms&rsquo; length sale of a Product to a Third Party in a country in the Territory following applicable Marketing Authorization
    for one or more indication(s) of such Product in such country, excluding for use in a clinical trial.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.32</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Force Majeure&rdquo; </B>shall mean failure or delay
    by any Party in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from
    fire, floods, embargoes, government regulations, prohibitions or interventions, war, acts of war (whether war be declared
    or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts, Third Party supplier failures, including
    unscheduled shut down of a reactor which is integral for the performance of BI&rsquo;s obligations hereunder, or any other
    cause beyond the reasonable control of the affected Party.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.33</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Generic Patents&rdquo; </B>shall mean Patent Case 100-7382
    and Patent Case 118-7595 (additional use patent), and any corresponding patent applications or patents including any and all
    substitutions, extensions, re-examination, or supplementary protection certificates, reissues, renewals, divisions, continuations
    or continuations-in-part thereof, provisional patents, patents of addition, or registrations of any kind, including but not
    limited to those set out in <B><U>Exhibit 1a</U></B><U>.</U> For reference purposes, and not by way of limitation, the foregoing
    Generic Patents relate to labeled somatostatin analogues.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.34</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Good Clinical Practice&rdquo;</B> or <B>&ldquo;GCP&rdquo;
    </B>shall mean the internationally recognized ethical and scientific standard for the design, conduct, performance, monitoring,
    auditing, recording, analyses and reporting of clinical trials that provides assurance that the data and reported results
    are credible and accurate and that the rights, integrity and confidentiality of the trial subjects are protected.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.35</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Good Manufacturing Practices&rdquo;</B> or <B>&ldquo;GMP&rdquo;
    </B>shall mean the then current Good Manufacturing Practices as such term is defined from time to time by the FDA or other
    relevant Regulatory Authority having jurisdiction over the development, manufacture or sale of the Product in the Territory
    pursuant to its regulations, guidelines or otherwise.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.36</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Interest&rdquo; </B>shall mean a rate per annum equal
    to LIBOR (London Interbank Offered Rate) plus one percent (1%) at the time such payment is due, and for the time period until
    payment is received by the Party entitled to receive such Interest</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="color: Black"><B>1.37</B></FONT></TD>
    <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;[*]&rdquo;</B> shall mean Dr. [*] of Rotterdam,
    The Netherlands.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B>1.38</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B>&ldquo;[*] License
    Agreement&rdquo;</B> shall mean the sublicense agreement entered into by and between [*] and BI, dated June 12, 2007 granting
    BI rights to the Generic Patents.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B>1.39</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B>&ldquo;MAA&rdquo;
    </B></FONT><FONT STYLE="color: Black">shall mean a Marketing Authorization Application filed with the EMEA or any regulatory
    authority in any other country other than the US that is responsible for review and approval of marketing applications for
    human drugs or diagnostics.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B>1.40</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B>&ldquo;Mallinckrodt
    Early Termination License&rdquo; </B></FONT><FONT STYLE="color: Black">shall have the meaning as set forth in <FONT STYLE="font-family: Times New Roman, Times, Serif">Section
    11.4(a).<B> </B></FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.41</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Mallinckrodt Milestone Payments&rdquo;</B> shall mean
    the milestone payments due from BI as set forth under Sections 5.2 and 5.3.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.42</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Mallinckrodt Patents&rdquo;</B> shall mean any issued
    patent and any pending patent application owned or Controlled by Mallinckrodt during the Term of this Agreement with a claim
    encompassing the Compound, the Product, or any claims or formulations related to the Product and Compound, processes, uses
    and intermediates for the foregoing and shall include any continuations, continuations-in-part, divisions, provisionals, substitutions,
    patents of addition, reissues, re-examinations, renewals or extensions thereof (including any supplemental patent certificates)
    and any confirmation patent or registration patent and all foreign counterparts of any of the foregoing, including but not
    limited to those set out in <B><U>Exhibit 1b</U></B>.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.43</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Mallinckrodt Royalties&rdquo;</B> shall mean the royalty
    payments due from BI as set forth under Section 5.4.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.44</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Marketing Authorization&rdquo;</B> shall mean, with respect
    to a country in the Territory, the approval by the appropriate Regulatory Authority necessary for the Commercialization of
    the Product in that country. For the sake of clarity, Marketing Authorization shall not include the reimbursement approval.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.45</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;NDA&rdquo;</B> or <B>&ldquo;New Drug Application&rdquo;
    </B>shall mean a new drug application and all amendments and supplements thereto filed with the FDA (as more fully defined
    in 21 C.F.R. 314.5 et seq.), or the equivalent application filed with any equivalent Regulatory Authority outside the US (including
    any supra-national agency such as EMEA) requiring such filing, including all documents, data and other information concerning
    the Product which are necessary for gaining Marketing Authorization.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.46</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;NDA Acceptance&rdquo;</B> shall mean the date upon which
    the Product NDA submitted by BI is accepted for filing by FDA or the equivalent dossier is accepted for review by any</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="color: Black">other country&rsquo;s respective Regulatory Authority,
    such as, for example, a Common Technical Document (&ldquo;CTD&rdquo;) submitted to the EMEA.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.47</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Net Sales&rdquo;</B> shall mean, with respect to the
    Product, the gross amount invoiced by or on behalf of the relevant Party or its Affiliates or Sublicensees for sales of the
    Product, during the Term hereof as set forth in Article 11, to Third Parties in bona fide, arms&rsquo;-length transactions,
    less the following customary deductions, each determined in accordance with the Accounting Standards:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="color: Black">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">normal
                                         and customary trade and quantity discounts actually allowed and properly taken directly
                                         with respect to sales of the Product; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 96pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="color: Black">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">amounts
                                         actually repaid or credited by reason of defects, rejection, recalls, returns, rebates
                                         and allowances of goods; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 96pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="color: Black">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">chargebacks
                                         and other amounts paid on sale or dispensing of Product; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 96pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="color: Black">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">amounts
                                         payable resulting from governmental mandated rebate programs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 96pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="color: Black">(v)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">tariffs,
                                         duties, excise, sales, value- added and other taxes (other than taxes based on income);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 96pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="color: Black">(vi)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">retroactive
                                         price reductions specifically identifiable to the Product that are actually allowed or
                                         granted;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 96pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="color: Black">(vii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">customary
                                         cash discounts for timely payment;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 96pt; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="color: Black">(viii)</FONT></TD><TD><FONT STYLE="color: Black">delayed ship order credits; all
                                         freight, postage and insurance included in the invoice price;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="color: Black">(ix)</FONT></TD><TD><FONT STYLE="color: Black">pharmacy service fees for services
                                         such as compounding fees for the preparation of radiopharmaceuticals and fees for the
                                         preparation of unit doses; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="color: Black">(x)</FONT></TD><TD><FONT STYLE="color: Black">discounts pursuant to indigent patient
                                         programs and patient discount programs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt"><FONT STYLE="color: Black">In the event the Product is
sold as a Combination Product, the Net Sales of the Product, for the purposes of determining royalty payments, shall be determined
by multiplying the Net Sales (as defined above in this Section) of the Combination Product by the fraction, A/(A+B) where A is
the weighted (by sales volume) average sale price in a particular country of the Product when sold separately in finished form
and B is the weighted average sale price in that country of the other product(s) sold separately in finished form. In the event
that such average sale price cannot be determined for both the Product and the other product(s) in combination, Net Sales for
purposes of determining royalty payments shall be negotiated in good faith and agreed upon by the Parties based on the relative
value contributed by each component.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="color: Black"><B>1.48</B></FONT></TD>
    <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Other Data Agreements&rdquo;</B> shall mean
    any agreement(s) between a Third Party and BI, other than the Erasmus License Agreement, which grant to BI rights in data
    relating to the Compound, the Product Components or the Product, including without limitation clinical data on patients treated
    with the Product, data on safety, efficacy and outcome, stability or manufacturing data of the Compound, the Product Components
    or the Product for inclusion in a New Drug Application for submission to Regulatory Authorities to obtain Marketing Authorization.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.49</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Party&rdquo; or &ldquo;Parties&rdquo;</B> shall mean
    BI or Mallinckrodt, or BI and Mallinckrodt, whichever the context admits.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.50</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Person&rdquo;</B> shall mean any individual or legal
    entity, including a corporation, partnership, association, joint-stock company, trust, unincorporated organization or government
    or political subdivision thereof.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.51</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Product&rdquo;</B> shall mean the lutetium-177 radiolabeled
    Compound for radio-therapeutic and dosimetric use in final therapy dosage form and ready for infusion into the patient by
    the customer.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.52</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&ldquo;<B>Product Components</B>&rdquo; shall mean the lutetium
    Lu 177 chloride sterile solution, the Product Reaction Vial and such other elements comprising the Product as defined in the
    NDA which are combined to form the lutetium-177 labeled Compound. As used in the preceding sentence, &ldquo;lutetium Lu 177
    chloride sterile solution&rdquo; shall mean the sterile radiochemical solution of the lutetium-177 radioisotope in a hydrochloric
    acid solution.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.53</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&ldquo;<B>Product Reaction Vial</B>&rdquo; shall mean the vial
    containing frozen or lyophilized material comprised of the Compound plus other additives necessary for a commercially stable
    formulation to which a lutetium-177 solution is added to make the Product.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.54</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Regulatory Authority&rdquo;</B> shall mean the FDA or
any foreign counterpart or additional governmental or regulatory agency in the Territory responsible for applicable Marketing
Authorization pharmacovigilance, reimbursement or other subject matters contemplated in this Agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.55</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>[Deleted pursuant to terms of Termination and Amendment attached
    hereto as Annex A.1]</B>.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.56</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&ldquo;<B>Specifications</B>&rdquo; shall mean the written standards
    for the Product and the Product Components as set forth in the NDA approved by a Regulatory Authority in connection with the
    Marketing Authorization of the Product or as set forth in a separate DMF.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.57</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Sublicensee&rdquo;</B> shall mean a Third Party to which
    either Party may grant a right or license to the Product or the Compound under all or part of the BI Intellectual Property
    or the Mallinckrodt Patents in the Territory, or delegate an obligation hereunder.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.58</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Term&rdquo;</B> shall have the meaning as set forth in
    Section 11.1.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="color: Black"><B>1.59</B></FONT></TD>
    <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Territory&rdquo;</B> shall mean all the countries
    and territories of the world.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.60</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;Third Party&rdquo;</B> shall mean any Person other than
    BI, Mallinckrodt, their respective Affiliates or permitted Sublicensees hereunder.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>1.61</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>&ldquo;US&rdquo; </B>shall mean the United States of America,
    including the District of Columbia, the Commonwealth of Puerto Rico and all other places under the jurisdiction thereof.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-style: normal; text-transform: uppercase; color: Black"><B>ARTICLE
2</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-style: normal; text-transform: uppercase; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-style: normal; text-transform: uppercase; color: Black"><B>LICENSE
</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: navy"><FONT STYLE="font-style: normal; text-transform: uppercase; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>2.1</B></FONT></TD>
    <TD STYLE="width: 92%; font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>Grant
    to BI.&nbsp;&nbsp;</B>In consideration of the payments provided for in this Agreement, and subject to the provisions of this
    Agreement, Mallinckrodt hereby grants to BI an exclusive, worldwide, royalty-bearing license in the Field under the Mallinckrodt
    Patents, with the right to grant sublicenses as provided below to Develop and Commercialize the Product and exercise its rights
    under this Agreement (&ldquo;<B>BioSynthema License Rights</B>&rdquo;).&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>2.2</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>Sublicense.
    </B>Under the BioSynthema License Rights, BI shall have the right to grant sublicenses to Third Parties including but not
    limited to sublicenses for the manufacturing of the Product, provided that the terms and conditions of a sublicense agreement
    shall be consistent with the terms of this Agreement. BI shall remain directly liable to Mallinckrodt for its obligations
    hereunder and shall be deemed a guarantor of each Sublicensee&rsquo;s performance of BI&rsquo;s obligations under this Agreement.&nbsp;&nbsp;BI
    shall strictly enforce each Sublicensee&rsquo;s performance of BI&rsquo;s obligations under this Agreement.&nbsp;&nbsp;Any
    sublicense by BI shall not waive any of BI&rsquo;s obligations to Mallinckrodt, nor waive any of Mallinckrodt&rsquo;s rights
    under this Agreement.&nbsp;&nbsp;Any reference to the obligations, performance, requirements or duties of BI hereunder shall
    be deemed applicable to and enforceable by either Party against any BI Sublicensee.&nbsp;&nbsp;In the event that BI assigns
    any of BI&rsquo;s rights or obligations under this Agreement to a Sublicensee, then BI shall promptly notify Mallinckrodt
    of that fact and of the extent of the involvement of the Sublicensee with regard to this Agreement.&nbsp;&nbsp;BI shall provide
    Mallinckrodt with such additional information regarding any such Sublicensee as may be reasonably requested by Mallinckrodt.
    </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>2.3</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>Limitations
    of Rights.</B> No license is granted by Mallinckrodt to BI other than the license expressly granted by the provisions of Section
    2.1. &nbsp;Mallinckrodt retains all other rights under the Mallinckrodt Patents.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>ARTICLE 3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"><FONT STYLE="color: Black">BioSynthema
shall utilize Commercially Reasonable Efforts to Develop and Commercialize the Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>ARTICLE 4</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">MANUFACTURE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>4.1</B></FONT></TD>
    <TD STYLE="width: 92%; font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>Manufacturing
    Responsibility.</B> BI shall be responsible, at its expense, for: (i) procuring all necessary materials required to manufacture
    the Compound, the Product Components and the Product; (ii) obtaining all licenses, permits or approvals required to manufacture
    the Compound, the Product Components and the Product; and (iii) manufacturing the Product in accordance with GMP to meet the
    requirements of the Development work hereunder, the requirements for patient use from and after the First Commercial Sale
    and in accordance with the Product Specifications as approved in each country in which the Product has Marketing Authorization.
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">ARTICLE 5</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">CONSIDERATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>5.1</B></FONT></TD>
    <TD STYLE="width: 92%; font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>[Deleted
    pursuant to terms of Termination and Amendment attached hereto as Annex A.1]</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>5.2</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>[Deleted
    pursuant to terms of Termination and Amendment attached hereto as Annex A.1]</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>5.3</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>[Deleted
    pursuant to terms of Termination and Amendment attached hereto as Annex A.1]</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>5.4</B></FONT></TD>
    <TD STYLE="font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>[Deleted
    pursuant to terms of Termination and Amendment attached hereto as Annex A.1] </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(a)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black"><B>[Deleted
                                         pursuant to terms of Termination and Amendment attached hereto as Annex A.1]</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(b)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black"><B>Royalty
                                         Term</B>. Royalties shall be payable within sixty (60) days of the end of each Calendar
                                         Quarter from the First Commercial Sale of the Product until 2020. Notwithstanding the
                                         foregoing, the royalties hereunder shall cease to be payable in a country to the extent
                                         that the Mallinckrodt Patents are held to be invalid by a court of competent jurisdiction
                                         in that country.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(c)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black"><B>[Deleted
                                         pursuant to terms of Termination and Amendment attached hereto as Annex A.1]</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>5.5</B></FONT></TD>
    <TD STYLE="width: 92%; font-weight: normal; text-align: justify; color: navy"><FONT STYLE="font-size: 10pt; color: Black"><B>Sales
    Reports. &nbsp;</B>After the first First Commercial Sale of Product, BI shall have the following sales report obligations:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(a)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black"><B>Substance
                                         of Reports.</B> Within sixty (60) days following the close of each Calendar Quarter,
                                         BI shall furnish to Mallinckrodt a written report showing the Net Sales in each country
                                         in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(b)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black"><B>Records.
                                         </B>BI shall keep accurate records in sufficient detail to enable the amounts</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">                                                                                                                                                                                                                                                                                                                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">due hereunder to be determined and to
                              be verified by an independent certified public accountant mutually agreed upon by the Parties pursuant
                              to Section 5.5(d).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(c)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black"><B>Currency
                                         Exchange</B>. All payments shall be made in U.S. Dollars. The U.S. Dollar equivalent
                                         of Net Sales invoiced in a currency other than U.S. Dollars shall be calculated in the
                                         same manner and using the same exchange rate as Mallinckrodt&rsquo;s ultimate parent
                                         company (Covidien) uses to translate its consolidated income statements into U.S. Dollars.
                                         The methodology employed by Covidien to translate its consolidated income statements
                                         into U.S. Dollars shall be in accordance with Accounting Standards.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; color: navy; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(d)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black"><B>Record
                                         Retention and Inspection. &nbsp;</B>Royalty payments shall be made to the address and to the
                                         Affiliate as Mallinckrodt may designate from time to time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 16%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(i)</FONT></TD><TD STYLE="text-align: justify; width: 76%"><FONT STYLE="color: Black">BI shall
                                         keep for two (2) years from the date of each payment of royalties complete and accurate
                                         records of sales by BI of Product in sufficient detail to allow the accruing royalties
                                         to be determined accurately.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 16%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(ii)</FONT></TD><TD STYLE="text-align: justify; width: 76%"><FONT STYLE="color: Black">Mallinckrodt
                                         shall have the right for a period of one (1) year after receiving any report or statement
                                         with respect to royalties due and payable to appoint an independent certified public
                                         accountant reasonably acceptable to BI to inspect the relevant records of BI and/or its
                                         Sublicensees (directly) to verify such report or statement. Mallinckrodt may exercise
                                         this right once with respect to the prior year&rsquo;s Net Sales. If the right is not
                                         exercised during the one (1) year period described, the report shall be deemed accepted.
                                         Mallinckrodt may exercise this right only once in any Calendar Year.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 16%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(iii)</FONT></TD><TD STYLE="text-align: justify; width: 76%"><FONT STYLE="color: Black">BI shall
                                         make its records available for inspection by such independent certified public accountant
                                         during regular business hours at such place or places where such records are customarily
                                         kept, upon reasonable notice from Mallinckrodt, solely to verify the accuracy of the
                                         reports and payments. The results of each inspection, if any, shall be binding on both
                                         Parties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 16%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(iv)</FONT></TD><TD STYLE="text-align: justify; width: 76%"><FONT STYLE="color: Black">Mallinckrodt
                                         agrees to hold in strict confidence and use only for the purpose described in this Article
                                         5 all information concerning royalty payments and reports, and all information learned
                                         in the course of any audit or inspection (and not to make copies of such reports and
                                         information), except to the extent necessary for Mallinckrodt to reveal such information
                                         in order to enforce its rights under this Agreement in a court of competent jurisdiction
                                         or if disclosure is required by law, regulation or judicial order or to Novartis Pharma
                                         AG (&ldquo;<B>Novartis</B>&rdquo;) as may be necessary for Mallinckrodt to comply with
                                         any contractual obligations to Novartis. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 16%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(v)</FONT></TD><TD STYLE="width: 76%"><FONT STYLE="color: Black">Mallinckrodt shall pay for such inspections,
                                         except that in the event there is any upward adjustment in aggregate royalties payable
                                         for any year shown by such inspection of more than [*] percent ([*]%) of the amount paid,
                                         BI shall pay for such inspection. BI shall immediately pay Mallinckrodt the amount of
                                         any underpayment revealed by the inspection; any overpayments shall be fully creditable
                                         against amounts payable in subsequent payment periods, or fully refunded by Mallinckrodt
                                         to BI in the event there are no further sales of Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 16%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(vi)</FONT></TD><TD STYLE="width: 76%"><FONT STYLE="color: Black">BI shall include in each Sublicense
                                         entered into by it pursuant to this Agreement a provision requiring the Sublicensee to
                                         keep and maintain adequate records of sales made pursuant to such sublicense and to grant
                                         BI access to such records for the purpose of BI inspecting such records for verification
                                         of Net Sales.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black"><B>5.6</B></FONT></TD><TD STYLE="text-align: justify; width: 92%"><FONT STYLE="color: Black"><B>Withholding
                                         Taxes. &nbsp;</B>In the event BI is required by law to make any deduction or withholding of
                                         taxes from any payment due to Mallinckrodt or its Affiliate under this Agreement, BI
                                         is authorized to withhold such taxes from the payments made under this Agreement at the
                                         applicable rate, taking into account any reduced rate of tax that Mallinckrodt or its
                                         Affiliate may be eligible for under applicable treaty or other applicable tax law; provided,
                                         however, Mallinckrodt shall provide to BI all necessary documentation establishing its
                                         eligibility for either (i) treaty benefits under an applicable treaty, or (ii) a reduction
                                         in or exemption from taxes under other applicable tax law.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black"><B>5.7</B></FONT></TD><TD STYLE="text-align: justify; width: 92%"><FONT STYLE="color: Black"><B>Interest
                                         Due.</B> <FONT STYLE="font-weight: normal"> &nbsp;All payments due by BI to Mallinckrodt, if
                                         not paid as specified in this Agreement shall accrue Interest until all such payments
                                         and Interest are paid. </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">ARTICLE 6</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">[Deleted pursuant
to terms of Termination and Amendment attached hereto as Annex A.1]</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">ARTICLE 7</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">INTELLECTUAL
PROPERTY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black"><B>7.1</B></FONT></TD><TD STYLE="text-align: justify; width: 92%"><FONT STYLE="color: Black"><B>Mallinckrodt
                                         Patents</B> <FONT STYLE="font-weight: normal">During the Term of this Agreement, Mallinckrodt
                                         shall be responsible for the prosecution and maintenance of Mallinckrodt Patents. </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 8%; text-align: left"><FONT STYLE="color: Black"><B>7.2</B></FONT></TD><TD STYLE="width: 92%"><FONT STYLE="color: Black"><B>Infringement
                                         Claims by Third Parties.</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="font-weight: normal; color: Black">(a)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black">Notice.
                                         <FONT STYLE="font-weight: normal">If the manufacture, use, marketing, promotion, importation,
                                         offer for sale, distribution or sale of Compound or Product results in a claim or a threatened
                                         claim by a Third Party against a Party hereto for patent infringement or for inducing
                                         or contributing to patent infringement (&ldquo;</FONT>Infringement Claim<FONT STYLE="font-weight: normal">&rdquo;),
                                         the Party first having notice of an Infringement Claim shall promptly notify the other
                                         </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%; text-align: left"></TD><TD STYLE="width: 84%"><FONT STYLE="font-weight: normal; color: Black">in</FONT> <FONT STYLE="font-weight: normal; color: Black">writing.
                                                                        The notice shall set forth the facts of the Infringement Claim in reasonable detail. Failure to give notice shall not
                                                                        constitute a defense, in whole or in part, to any claim by any indemnified person hereunder except to the extent the rights
                                                                        of the indemnifier are materially prejudiced by such failure to give notice.</FONT></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">                                                                                                                                                                                                                                                                                                                                                                                                                                 
<TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="font-weight: normal; color: Black">(b)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black">Litigation.
&nbsp;                                         <FONT STYLE="font-weight: normal">The Parties will promptly meet to discuss the lawsuit.
                                         BI shall defend any such infringement suit and will pay all losses, damages, costs, and
                                         expenses, including attorney's fees, that may be incurred by BI in the defense or settlement
                                         of the litigation. Mallinckrodt will cooperate fully, at BI&rsquo;s expense, with BI
                                         in defending any such litigation for patent infringement. If BI should decide to settle
                                         any such litigation, it will notify Mallinckrodt of the proposed terms of any such proposed
                                         settlement and Mallinckrodt may agree to such proposed settlement or Mallinckrodt will
                                         assume the prosecution of the litigation and assume complete responsibility for all subsequent
                                         expenses, damages and judgments. If any settlement of the litigation results in an obligation
                                         on the part of BI to pay license fees or royalties to a Third Party, BI shall not reduce
                                         the royalty rate otherwise owed to Mallinckrodt. In addition, the Party not controlling
                                         such defense will have the right to be represented in any such action by counsel of its
                                         choosing at its own expense. The Party controlling such defense shall keep the other
                                         Party advised of the status of such action and shall consider recommendations made by
                                         the other Party in respect thereto. </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 8%; text-align: left"><FONT STYLE="color: Black"><B>7.3</B></FONT></TD><TD STYLE="width: 92%"><FONT STYLE="color: Black"><B>Infringement
                                         Claims Against Third Parties</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="font-weight: normal; color: Black">(a)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black">Notice<FONT STYLE="font-weight: normal">.
                                         &nbsp;If either Party becomes aware that any Third Party is (or is reasonably likely to be)
                                         infringing any Mallinckrodt Patents, or BI Intellectual Property, the Party to this Agreement
                                         first having knowledge of such infringement, or knowledge of a reasonable probability
                                         of such infringement, shall promptly notify the other in writing. The notice shall set
                                         forth the facts of such infringement in reasonable detail. </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="font-weight: normal; color: Black">(b)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black">Institution
                                         of Proceedings<FONT STYLE="font-weight: normal">. Mallinckrodt shall have the right,
                                         but not the obligation, to institute, prosecute, and control with its own counsel at
                                         its own expense any action or proceeding with respect to infringement of the claims of
                                         the Mallinckrodt Patents. BI shall have the right, but not the obligation, to institute,
                                         prosecute, and control with its own counsel at its own expense any action or proceeding
                                         with respect to infringement of the claims of the BI Intellectual Property. In the event
                                         the respective Party does not take any action with respect to any such infringement within
                                         120 days after receiving notice of such infringement thereof, the other Party may at
                                         its own discretion and at its own expense undertake such prosecution thereof. The Party
                                         undertaking the prosecution shall have the sole charge and direction of the prosecution
                                         of any such suit or action and the other Party shall, at its own expense, have the right,
                                         but not the obligation, to be represented in such action by its own counsel acting in
                                         an advisory but not controlling capacity. Each Party agrees to cooperate fully in the
                                         prosecution of any such suit or action undertaken hereunder by the other Party and to
                                         provide all evidence in its reasonable control. The Party controlling any </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.13in; text-align: justify"><FONT STYLE="font-weight: normal; color: Black">such
legal proceedings shall, at the request of the other Party and to the extent permitted by law, direct its counsel to provide the
other Party copies of all pleadings, discovery, and any other filings made or received in such legal proceedings. In addition,
the Party controlling such legal proceedings may name the other Party as a party plaintiff as required by law and, if so required,
shall pay the reasonable costs of representation solely for the purposes of prosecuting the lawsuit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="font-weight: normal; color: Black">(c)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black">Division
                                         of Settlement / Damages Award.<FONT STYLE="font-weight: normal"> &nbsp;Each Party shall recover
                                         their respective actual out-of-pocket expenses, or equitable proportions thereof, associated
                                         with any litigation or settlement thereof from any recovery made by any Party. Any excess
                                         amount allocated as a damage award or settlement recovery shall be shared equally between
                                         the Parties. </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="font-weight: normal; color: Black">(d)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black">Settlement
                                         Status<FONT STYLE="font-weight: normal">. The Parties shall keep each other informed
                                         of the status of, and of their respective activities regarding, any litigation or settlement
                                         thereof concerning the Compound and/or Product; provided, however, that no settlement
                                         or consent judgment or other voluntary final disposition of a suit under this Article
                                         7 may be undertaken without the consent of the other Party if such settlement would require
                                         the other Party to be subject to an injunction or to make a monetary payment or would
                                         otherwise adversely affect the other Party&rsquo;s rights under this Agreement. </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">7.4</FONT></TD><TD STYLE="text-align: justify; width: 92%"><FONT STYLE="color: Black">Patent Term
                                         Extensions<FONT STYLE="font-weight: normal">. The Parties shall cooperate in good faith
                                         with each other in procuring a patent term extension, wherever applicable, to the Mallinckrodt
                                         Patents. In the event that Mallinckrodt, which is responsible for prosecution and maintenance
                                         of the Mallinckrodt Patents, elects not to file for an extension, Mallinckrodt shall
                                         (i) inform BI of its intention not to file and (ii) cooperate with BI to file for such
                                         extension if the law requires such filing be made by Mallinckrodt or grant BI the right
                                         to file for such extension.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt; color: Black">7.5</FONT></TD><TD STYLE="text-align: justify; width: 92%"><FONT STYLE="font-size: 10pt; color: Black">BI
                                         Intellectual Property<FONT STYLE="font-weight: normal">. During the Term of this Agreement,
                                         BI New Intellectual Property shall be owned by BI and BI shall at its discretion be responsible
                                         for the filing, prosecution and maintenance of any patents or patent applications granted/filed
                                         on inventions or discoveries made by BI during the Development of the Compound and the
                                         Product. BI will disclose promptly to Mallinckrodt, in writing, all such inventions and
                                         discoveries made or conceived by BI personnel/representatives, and</FONT> <FONT STYLE="font-weight: normal">any
                                         such new patent applications filed.</FONT> <FONT STYLE="font-weight: normal">Such written
                                         disclosures shall include the names of all inventor(s) and/or developer(s). Such written
                                         disclosures shall be held in confidence by Mallinckrodt and BI. BI shall provide Mallinckrodt
                                         copies of drafts of such patent applications and copies of all prosecution documents
                                         in a timely manner prior to its filing in order to permit Mallinckrodt a reasonable time
                                         period to review such patent applications or prosecution documents and, at Mallinckrodt&rsquo;s
                                         discretion, provide BI reasonable technical assistance in the preparation and prosecution
                                         of such patent applications.</FONT></FONT><FONT STYLE="font-weight: normal; color: Black">
                                         <FONT STYLE="font-size: 10pt"> </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">ARTICLE 8</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">REPRESENTATIONS
AND WARRANTIES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 8%; text-align: left"><FONT STYLE="color: Black">8.1</FONT></TD><TD STYLE="width: 92%"><FONT STYLE="color: Black">Mallinckrodt Representations
and Warranties<FONT STYLE="font-weight: normal">. &nbsp;Mallinckrodt represents and warrants to BI as follows with respect to Mallinckrodt&rsquo;s
performance of its obligations under this Agreement:</FONT></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="font-weight: normal; color: Black">(a)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="font-weight: normal; color: Black">This
                                         Agreement has been duly executed and delivered by Mallinckrodt and constitutes the valid
                                         and binding obligation of Mallinckrodt, enforceable against Mallinckrodt in accordance
                                         with its terms except as enforceability may be limited by bankruptcy, fraudulent conveyance,
                                         insolvency, reorganization, moratorium and other laws relating to or affecting creditors&rsquo;
                                         rights generally and by general equitable principles. The execution, delivery and performance
                                         of this Agreement have been duly authorized by all necessary action on the part of Mallinckrodt,
                                         its officers and directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt; color: Black">(b)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">Mallinckrodt
                                         is the owner of, or Controls, and it will maintain during the Term, the entire right,
                                         title and interest in and to the Mallinckrodt Patents and it has the right to grant the
                                         licenses described in the License Agreement and as described herein and the grant of
                                         such licenses will not result in a breach of any agreement, contract or other understanding
                                         of any nature whatsoever to which Mallinckrodt is a party. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="font-weight: normal; color: Black">(c)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="font-weight: normal; color: Black">Having
                                         no duty to conduct due diligence, Mallinckrodt has no knowledge as of the date of this
                                         Agreement of any patent applications, valid issued patents or other intellectual property
                                         rights owned by any Third Party which adversely affects Mallinckrodt&rsquo;s obligations
                                         under this Agreement, the licenses granted hereunder, the Mallinckrodt Patents, and specifically,
                                         Mallinckrodt does not have any knowledge that practicing the Mallinckrodt Patents will
                                         constitute an infringement of any Third Party&rsquo;s valid and enforceable rights.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(d)</FONT></TD><TD STYLE="width: 84%"><FONT STYLE="color: Black">Having no duty to conduct due diligence,
                                         Mallinckrodt does not have any knowledge of any prior art, public use, prior offering
                                         for sale, presentation, publication or any other act that would adversely affect the
                                         validity of, or limit the scope of, any pending or issued claims of, the Mallinckrodt
                                         Patents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(e)</FONT></TD><TD STYLE="width: 84%"><FONT STYLE="color: Black">Mallinckrodt is not currently a
                                         Party to, and during the Term of this Agreement will not enter into, any agreements,
                                         oral or written, that are inconsistent with its obligations under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(f)</FONT></TD><TD STYLE="width: 84%"><FONT STYLE="color: Black">Mallinckrodt is duly organized and
                                         validly existing under the laws of the State of Delaware and has full legal power and
                                         authority to enter into this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(g)</FONT></TD><TD STYLE="width: 84%"><FONT STYLE="color: Black">Mallinckrodt is not subject to any
                                         order, decree or injunction by a court of competent jurisdiction which prevents or materially
                                         delays the consummation of the transactions contemplated by this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black"><B>8.2</B></FONT></TD><TD STYLE="width: 92%"><FONT STYLE="color: Black"><B>BI Representations and Warranties</B>.
                                         &nbsp;BI represents and warrants to Mallinckrodt as follows with respect to the performance
                                         of its obligations under this Agreement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(a)</FONT></TD><TD STYLE="width: 84%"><FONT STYLE="color: Black">This Agreement has been duly executed
                                         and delivered by BI and constitutes the valid and binding obligation of BI, enforceable
                                         against BI in accordance with its terms except as enforceability may be limited by bankruptcy,
                                         fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating
                                         to or affecting creditors&rsquo; rights generally and by general equitable principles.
                                         The execution, delivery and performance of this Agreement have been duly authorized by
                                         all necessary action on the part of BI, its officers and directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(b)</FONT></TD><TD STYLE="width: 84%"><FONT STYLE="color: Black">BI is not currently a Party to,
                                         and during the Term of this Agreement will not enter into, any agreements, oral or written,
                                         that are inconsistent with its obligations under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(c)</FONT></TD><TD STYLE="width: 84%"><FONT STYLE="color: Black">BI is duly organized and validly
                                         existing under the laws of the State of Missouri and has full legal power and authority
                                         to enter into this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="font-weight: normal; color: Black">(d)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="font-weight: normal; color: Black">BI
                                         is not subject to any order, decree or injunction by a court of competent jurisdiction
                                         which prevents or materially delays the consummation of the transactions contemplated
                                         by this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(e)</FONT></TD><TD STYLE="width: 84%"><FONT STYLE="color: Black">BI has entered into the [*] License
                                         Agreement and has thereby acquired valid and enforceable rights to the Generic Patents
                                         (listed in <B><U>Exhibit 1a</U></B>). A true and correct copy of the [*] License Agreement
                                         has been delivered to Mallinckrodt prior to the Effective Date hereof, with financial
                                         information redacted. BI represents and warrants that it has the right to enforce, or
                                         the right to cause to be enforced, the Generic Patents and the patents licensed under
                                         any Third Party license agreements that are listed in <B><U>Exhibit 2</U></B> against
                                         a Third Party infringer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(f)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black">BI has
                                         entered the Erasmus License Agreement and the Other Data Agreements and has thereby acquired
                                         valid and enforceable right, title and interest in and to all of the clinical data described
                                         therein. A true and correct copy of the Erasmus License Agreement and the Other Data
                                         Agreements has been delivered to Mallinckrodt prior to the Effective Date hereof, with
                                         financial information redacted.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 8%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black">(g)</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black">BI has
                                         the right, under the [*] License Agreement, the Erasmus License Agreement and any Other
                                         Data Agreements, to sublicense the BI Intellectual Property to Mallinckrodt during the
                                         Term hereof, and shall have the right to sublicense to Mallinckrodt under any BI New
                                         Intellectual Property during the Term.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 8%"><FONT STYLE="color: Black"><B>8.3</B></FONT></TD><TD STYLE="text-align: justify; width: 92%"><FONT STYLE="color: Black"><B>THE
                                         LIMITED WARRANTIES CONTAINED IN THIS ARTICLE ARE THE SOLE WARRANTIES GIVEN BY THE PARTIES
                                         AND ARE MADE EXPRESSLY IN LIEU OF AND EXCLUDE ANY IMPLIED WARRANTIES OF MERCHANTABILITY,
                                         FITNESS FOR A PARTICULAR PURPOSE, TITLE, </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black"><B>INFRINGEMENT
OR OTHERWISE, AND ALL OTHER EXPRESS OR IMPLIED REPRESENTATIONS AND WARRANTIES PROVIDED BY COMMON LAW, STATUTE OR OTHERWISE ARE
HEREBY DISCLAIMED BY BOTH PARTIES. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="color: Black"><B>ARTICLE
9</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="color: Black"><B>CONFIDENTIALITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>9.1</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Confidentiality</B>.
                                         &nbsp;Subject to the exercise of the licenses granted in Article 2, during the Term of this
                                         Agreement, and for a period of five (5) years thereafter each Party hereto will maintain
                                         in confidence all Confidential Information generated under this Agreement as well as
                                         any Confidential Information disclosed by the other Party hereto. Neither Party shall
                                         use, disclose or grant use of such Confidential Information except as required under
                                         this Agreement. Each Party shall use the same standard of care as it uses to protect
                                         its own Confidential Information to ensure that its and its Affiliates&rsquo; employees,
                                         agents, consultants, Sublicensee(s) and clinical investigators only make use of Confidential
                                         Information for the purpose of this Agreement and do not disclose or make any unauthorized
                                         use of such Confidential Information. Each Party shall promptly notify the other upon
                                         discovery of any unauthorized use or disclosure of Confidential Information. Confidential
                                         Information shall not include any information which and to the extent:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">was
                                         already known to the receiving Party, other than under an obligation of confidentiality,
                                         at the time of disclosure by the other Party;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">was
                                         generally available to the public or otherwise part of the public domain at the time
                                         of its disclosure to the other Party;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">becomes
                                         generally available to the public or otherwise part of the public domain after its disclosure
                                         and other than through any act or omission of the receiving Party in breach of this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">was
                                         disclosed to the receiving Party, by a Third Party who had no obligation to the other
                                         Party not to disclose such information; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">was
                                         independently developed by the receiving Party without reference to the disclosure by
                                         the other Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>9.2</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The
                                         Parties agree that the financial terms of the Agreement and the reports described in
                                         Section 3.1.2<B> </B>shall be considered Confidential Information of both Parties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>9.3</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Each
                                         Party may disclose the Confidential Information to the extent such disclosure is reasonably
                                         necessary in filing or prosecuting patent applications, prosecuting or defending litigation,
                                         or complying with any applicable statute or governmental regulation provided such Party
                                         has given the disclosing Party prompt written notice allowing it to limit such disclosure.
                                         In addition, either Party may disclose Confidential Information to</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black">its Affiliates
and to its Sublicensees; provided, however, in connection with any such disclosure the disclosing Party shall secure the same
obligations of confidential treatment of such Confidential Information, as required in this Article 9. BI may disclose all the
terms of this Agreement and the License Agreement to a Third Party for the purpose of seeking financial assistance and investment,
and shall obligate such Third Parties to treat such information as Confidential in accordance with this Article 9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>9.4</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The
                                         Parties shall undertake to ensure that all their employees who have access to Confidential
                                         Information of the other Party are under obligations of confidentiality fully consistent
                                         with those provided in this Article.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>9.5</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">BI
                                         agrees that the terms, including but not limited to the financial terms, may be disclosed
                                         by Mallinckrodt to Novartis without further notice, provided Novartis shall be subject
                                         to the same confidentiality obligations as set forth herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>ARTICLE 10</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>ANNOUNCEMENT
AND PUBLICITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>10.1</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Except
                                         upon agreement of both Parties, neither Party hereto shall make any disclosure to any
                                         Third Party, including press releases, concerning the terms of this Agreement. The restrictions
                                         on disclosure specified herein shall not apply to announcements required by law or regulations
                                         or stock exchange rules, including announcements required by law, regulations or stock
                                         exchange rules to be made by either Party to their respective shareholders. It is, however,
                                         the Parties&rsquo; intent that they will coordinate to such extent as may be reasonably
                                         possible with respect to the wording of any such announcements and that the financial
                                         terms of this Agreement shall not be made public.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>10.2</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Except
                                         with Mallinckrodt&rsquo;s prior written permission, BI shall not use and shall prohibit
                                         its Sublicensees from using Mallinckrodt&rsquo;s or its Affiliates&rsquo; name, symbols
                                         and any other marks in any form of publicity.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>ARTICLE 11</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>TERM AND TERMINATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>11.1</B></FONT></TD><TD><FONT STYLE="color: Black"><B>Term</B>. Unless otherwise
                                         terminated as provided under this Article 11 or under Section 15.2 (Force Majeure), the
                                         term of the Agreement shall commence as of the Effective Date and shall remain in full
                                         force and effect through January 1, 2020 (&ldquo;Term&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">11.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Termination
                                         For Insolvency<FONT STYLE="font-weight: normal">. Either Party may terminate this Agreement
                                         immediately upon delivery of written notice to the other Party (a) upon a finding of
                                         insolvency, receivership or bankruptcy by a competent court, for the settlement of the
                                         other Party's debts, (b) upon the other Party's making an assignment for the benefit
                                         of creditors, or (c) upon the other Party's dissolution or ceasing to do business. </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="color: Black">11.3</FONT></TD><TD><FONT STYLE="color: Black">Material Breach<FONT STYLE="font-weight: normal">.
&nbsp;If either Party is in breach of any material obligation hereunder and, in the case of a breach capable of remedy, it shall not
h&#9;ave been remedied by the defaulting Party within ninety (90) days of written notice specifying the breach and requiring its
remedy, the Party not in breach of the material obligation may forthwith terminate this Agreement by notice without prejudice
to the accrued rights of either Party, with rights to each Party as set forth in Section 11.4 below.</FONT></FONT></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="color: Black">11.4</FONT></TD><TD><FONT STYLE="color: Black">Effect Of Termination.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Termination
                                         by Mallinckrodt</B>.<B> </B>Upon early termination pursuant to Section 11.2, 11.3 or
                                         15.2, if Mallinckrodt is the terminating Party, all of Mallinckrodt&rsquo;s rights in
                                         the Mallinckrodt Patents shall revert to Mallinckrodt and Mallinckrodt shall automatically
                                         be granted a perpetual, worldwide, royalty-bearing, exclusive license, with the right
                                         to sub-license, in and to the BI Intellectual Property, except expressly excluding the
                                         Generic Patents, to Develop, make, have made, use, offer to sell, import and sell the
                                         Compound, the Product Components and the Product in the Territory in the Field. BI shall
                                         assign to Mallinckrodt all of BI&rsquo;s rights in and to any Third Party Sublicenses
                                         granted to BI in connection with its performance of the obligations hereunder. At Mallinckrodt&rsquo;s
                                         election, BI shall transfer to Mallinckrodt upon Mallinckrodt&rsquo;s request all its
                                         stock of Compound, Product Reaction Vials, Product labeling, package inserts and packaging
                                         at cost, and will immediately transfer ownership of all Marketing Authorizations to Mallinckrodt
                                         and to the extent possible, shall give Mallinckrodt and its Sublicensees an access right
                                         to all clinical development, regulatory and manufacturing data of the Product, as well
                                         as to all other relevant information Controlled by BI regarding the Compound, the Product
                                         Reaction Vials and the Product, as necessary to Develop, manufacture and Commercialize
                                         the Product (the foregoing rights and assets are collectively referred to herein as the
                                         &ldquo;<B>Mallinckrodt Early Termination License</B>&rdquo;).<B> </B>In addition, BI
                                         shall provide at Mallinckrodt&rsquo;s request, the reasonable assistance of appropriate
                                         BI personnel in connection with the transfer therewith.<B> </B>The royalty rate payable
                                         by Mallinckrodt to BI for the Mallinckrodt Early Termination License shall be as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(A)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">[*] percent
                                         ([*]%) of the annual Net Sales of the Product for a period of time and upon terms as
                                         set forth in Section 5.4.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(b)</FONT></TD><TD><FONT STYLE="color: Black"><B>Mallinckrodt&rsquo;s Right of
                                         First Offer on BI&rsquo;s Product Manufacturing Assets</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(i)</FONT></TD><TD><FONT STYLE="color: Black">If Mallinckrodt terminates this Agreement
                                         under Article 11 or under Section 15.2, then, in addition to the Mallinckrodt Early Termination
                                         License, Mallinckrodt shall have ninety (90) days after the date of such termination
                                         to provide a written offer to BI (the &ldquo;<B>Mallinckrodt Proposal</B>&rdquo;). The
                                         Mallinckrodt Proposal shall contain material terms for a transaction to acquire ownership
                                         of, or a license to, all of the assets of BI used in the manufacture of the Product,
                                         including the BI Intellectual Property related thereto, not otherwise acquired by or
                                         licensed to Mallinckrodt under the Mallinckrodt Early Termination License (the &ldquo;<B>Product
                                         Manufacture Assets</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(ii)</FONT></TD><TD><FONT STYLE="color: Black">If the Mallinckrodt Proposal is not
                                         received within the ninety (90) day response period or if Mallinckrodt notifies BI in
                                         writing that Mallinckrodt declines to extend such an offer, then BI shall have the unrestricted
                                         and irrevocable right thereafter to pursue an option to sell or license the Product Manufacture
                                         Assets to a Third Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(iii)</FONT></TD><TD><FONT STYLE="color: Black">If Mallinckrodt does provide a Mallinckrodt
                                         Proposal within the ninety (90) day response period, then BI and Mallinckrodt shall have
                                         a further sixty (60) days to negotiate exclusively and in good faith the terms of a business
                                         arrangement with respect to the Product Manufacture Assets.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(iv)</FONT></TD><TD><FONT STYLE="color: Black">If BI and Mallinckrodt are unable
                                         to reach an agreement within such sixty (60) day period, then BI shall so notify Mallinckrodt,
                                         and BI shall have the right thereafter to negotiate with (but not disclose the terms
                                         of the Mallinckrodt Proposal to) any Third Party and consider such proposal from a Third
                                         Party containing the material terms on which the Third Party proposes to enter into a
                                         business arrangement with respect to the Product Manufacture Assets. In the event of
                                         any such Third Party proposal which is acceptable to BI and which is received by BI within
                                         twelve (12) months of the date of termination as provided in subparagraph (i) above (the
                                         &ldquo;<B>Third Party Proposal</B>&rdquo;), BI shall give written notice thereof to Mallinckrodt
                                         and Mallinckrodt shall have thirty (30) days thereafter to offer to BI in writing terms
                                         that are in BI&rsquo;s sole, good faith determination better terms than that offered
                                         in the Third Party Proposal.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(v)</FONT></TD><TD><FONT STYLE="color: Black">If BI accepts Mallinckrodt&rsquo;s
                                         offer for the Product Manufacture Assets, then BI and Mallinckrodt shall negotiate in
                                         good faith within thirty (30) days thereafter with the intent of entering into a binding
                                         agreement to execute such transaction and all necessary documents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(vi)</FONT></TD><TD><FONT STYLE="color: Black">If BI and Mallinckrodt do not enter
                                         into a binding agreement as provided in subparagraph (v) above, then BI shall have no
                                         further obligation to Mallinckrodt for the sale of the Product Manufacturing Assets under
                                         this Agreement</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Termination
                                         by BI</B>. Upon early termination by BI pursuant to Section 11.2 or 11.3, BI shall be
                                         granted a perpetual, worldwide, royalty-bearing, exclusive license, with the right to
                                         sub-license in and to the Mallinckrodt Patents existing as of the date of such termination
                                         to make, have made, use, offer to sell, import and sell Product in the Territory in the
                                         Field (the &ldquo;<B>BI Early Termination License</B>&rdquo;).<B> </B>The royalty rate
                                         payable by BI for the BI Early Termination License shall be as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(A)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The applicable
                                         percentage as set forth in Section 5.4, reduced by [*] percent ([*]%) and payable upon
                                         the same terms and conditions as set forth in Section 5.4.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>ARTICLE 12</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>INDEMNIFICATION
AND INSURANCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>12.1</B></FONT></TD><TD><FONT STYLE="color: Black">BI will indemnify, defend and
                                         hold Mallinckrodt harmless from and against any and all Damages incurred or suffered
                                         by Mallinckrodt arising out of or resulting from: (i) BI&rsquo;s breach of a material
                                         term of this Agreement; (ii) BI&rsquo;s breach of any of its representations or warranties
                                         hereunder; (iii) BI&rsquo;s performance of its obligations hereunder, including the Development,
                                         manufacture, handling, use, marketing, sale or other disposition, of Compound, Product
                                         Component and/or Product by any of BI, its Sublicensees, and their contractors; (iv)
                                         any actual or alleged bodily injury, illness or death sustained in connection with the
                                         use of the Product; or (v) BI&rsquo;s breach of any of its obligations under the [*]
                                         License Agreement, the Erasmus License Agreement, any Third Party license agreement(s)
                                         or any Other Data Agreement(s), except to the extent that such Damages are due to Mallinckrodt&rsquo;s
                                         or Mallinckrodt&rsquo;s directors&rsquo;, officers&rsquo;, or employees&rsquo; negligence
                                         or willful misconduct.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>12.2</B></FONT></TD><TD><FONT STYLE="color: Black">Mallinckrodt will indemnify,
                                         defend and hold BI harmless from and against any and all Damages incurred or suffered
                                         by BI arising out of or resulting from: (i) Mallinckrodt&rsquo;s breach of a material
                                         term of this Agreement; (ii) Mallinckrodt&rsquo;s breach of any of its representations
                                         or warranties hereunder, or (iii) Mallinckrodt&rsquo;s breach of any its obligations
                                         with Novartis; except to the extent that such Damages are due to BI&rsquo;s or BI&rsquo;s
                                         directors&rsquo;, officers&rsquo;, or employees&rsquo; negligence or willful misconduct.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>12.3</B></FONT></TD><TD><FONT STYLE="color: Black">The Parties agree as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(a)</FONT></TD><TD><FONT STYLE="color: Black">Each Party shall give the other
                                         Party prompt written notice of any claim or threat of claim it receives with respect
                                         to any matter for which it may be entitled to indemnification, and the indemnifier shall
                                         thereafter defend or settle (subject to the terms of this Section 12.3) any such claim
                                         at the indemnifier&rsquo;s sole expense, with counsel selected by the indemnifier. In
                                         the defense or settlement of any such</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"><FONT STYLE="color: Black">claim, the indemnified Party
shall cooperate with and assist the indemnifier to the extent reasonably possible, but the indemnifier shall bear and pay any
and all expenses incurred by the indemnified Party in providing such cooperation and assistance, either directly or upon request
of the indemnified Party who has incurred such expense. Failure to give notice shall not constitute a defense, in whole or in
part, to any claim by any indemnified person hereunder except to the extent the rights of the indemnifier are materially prejudiced
by such failure to give notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(b)</FONT></TD><TD><FONT STYLE="color: Black">Notwithstanding the foregoing, upon
                                         any claim being made by a person not a Party to this Agreement (and not an Affiliate
                                         of a Party) with respect to any matter to which the foregoing indemnities relate, the
                                         indemnified Party may make settlement of such claim on not less than thirty (30) days
                                         prior written notice of the proposed terms thereof to the indemnifier; provided, however,
                                         that if within said thirty (30) day period the indemnifier shall have requested the indemnified
                                         Party not to settle such claim and to deny such claim, the indemnified Party will promptly
                                         comply and the indemnifier shall have the right to defend the claim at the indemnifier&rsquo;s
                                         sole expense and with counsel reasonably acceptable to the indemnified Party. In the
                                         event that the indemnifier has not responded to such notice within such 30-day period,
                                         such absence of response shall be deemed a written consent to the proposed settlement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(c)</FONT></TD><TD><FONT STYLE="color: Black">Notwithstanding that the indemnifier
                                         has assumed the defense of any claim with counsel selected by the indemnifier, the indemnified
                                         Party shall have the right to employ its own counsel, at its sole expense. If, in good
                                         faith, an indemnified Party concludes that there are specific defenses available to the
                                         indemnified Party which are different from or in addition to those available to the indemnifier
                                         with respect to the scope of the foregoing indemnities, then such indemnified Party shall
                                         have the right to direct the defense of any such defense of any such claim and each Party
                                         shall pay all its Damages.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(d)</FONT></TD><TD><FONT STYLE="color: Black">Neither Party will conduct itself
                                         in a way that could prejudice the defense of any such claims or threats.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>12.4</B></FONT></TD><TD><FONT STYLE="color: Black">References in this Article 12
                                         to a Party that may be entitled to indemnification shall also include its Affiliates
                                         and its and their officers, directors, employees and agents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>12.5</B></FONT></TD><TD><FONT STYLE="color: Black">The Parties agree to maintain
                                         insurance, including but not limited to product liability insurance and clinical trial
                                         insurance in the case of BI, with respect to their activities hereunder. Such insurance
                                         shall be in such amounts and subject to such deductibles based upon standards prevailing
                                         in the industry at the time. Mallinckrodt may satisfy its obligations under this Article
                                         through self-insurance to the same extent. BI shall, upon request by Mallinckrodt from
                                         time to time, produce a certificate of insurance evidencing such insurance coverage.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>12.6</B></FONT></TD><TD><FONT STYLE="color: Black">Neither Party nor its Affiliates
                                         shall have any liability for any special, incidental, or consequential damages, including,
                                         but not limited to the loss of opportunity, revenue or profit, in connection with or
                                         arising out of this Agreement, even if it shall have been advised of the possibility
                                         of such damages.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="color: Black"><B>ARTICLE
13</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="color: Black"><B>INFORMATION
ON CLINICAL SAFETY AND EPIDEMIOLOGY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>13.1</B></FONT></TD><TD><FONT STYLE="color: Black">BI shall be fully responsible
                                         for ensuring compliance with all pharmacovigilance obligations, including the holding
                                         and maintaining of the global safety database for the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="color: Black"><B>ARTICLE
14</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="color: Black"><B>GOVERNING
LAW AND JURISDICTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>14.1</B></FONT></TD><TD><FONT STYLE="color: Black">The construction, validity and
                                         performance of this Agreement will be governed in all respects by Missouri Law. All disputes
                                         arising out of or affecting this Agreement which cannot be resolved amicably shall be
                                         submitted to the exclusive jurisdiction of the State courts of Missouri (County of St.
                                         Louis) or (at the option of either Party) Federal District Court for the Eastern District
                                         of Missouri.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">ARTICLE 15</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">MISCELLANEOUS
PROVISIONS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">15.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Waiver.
                                         <FONT STYLE="font-weight: normal">The failure on the part of BI or Mallinckrodt to exercise
                                         or enforce any rights conferred upon it hereunder shall not be deemed to be a waiver
                                         of any such rights nor operate to bar the exercise or enforcement thereof at any time
                                         or times thereafter. The observance of any term of this Agreement may be waived (either
                                         generally or in a particular instance and either retroactively or prospectively) by the
                                         Party entitled to enforce such term, but any such waiver shall be effective only if in
                                         writing signed by the waiving Party.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">15.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Force Majeure.
                                         <FONT STYLE="font-weight: normal">Neither Party shall be held liable or responsible to
                                         the other Party nor be deemed to have defaulted under or breached this Agreement for
                                         failure or delay in fulfilling or performing any term of this Agreement, other than an
                                         obligation to make a payment, when such failure or delay is caused by reason of Force
                                         Majeure. If a Force Majeure circumstance persists for more than six (6) consecutive months,
                                         the Party not claiming the delay shall be entitled to terminate this Agreement effective
                                         upon the </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-weight: normal; color: Black">expiration
of such six (6) month period, provided that the terminating Party provide at least thirty (30) days prior written notice before
the effective date of such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>15.3</B></FONT></TD><TD><FONT STYLE="color: Black"><B>Severability</B>. The Parties
                                         shall comply with all Applicable Laws, domestic or foreign in connection with the performance
                                         of their respective obligations hereunder. In the event that any provision of this Agreement,
                                         or any part hereof, is found invalid or unenforceable, the remainder of this Agreement
                                         will be binding on the Parties hereto, and will be construed as if the invalid or unenforceable
                                         provision or part thereof had been deleted, and the Agreement shall be deemed modified
                                         to the extent necessary to render the surviving provisions enforceable to the fullest
                                         extent permitted by law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>15.4</B></FONT></TD><TD><FONT STYLE="color: Black"><B>Assignment</B>. This Agreement
                                         may not be assigned or otherwise transferred by either Party without the prior written
                                         consent of the other Party; provided, however, that either Party may assign this Agreement,
                                         without the consent of the other Party, (i) to any of its Affiliates, if the assigning
                                         Party guarantees the full performance of its Affiliates&rsquo; obligations hereunder
                                         or (ii) in connection with the transfer or sale of all or substantially all of its assets
                                         or business to which this Agreement pertains or in the event of its merger or consolidation
                                         with another company. In all cases the assigning Party shall provide the other Party
                                         with prompt notice of any such assignment. Any purported assignment in contravention
                                         of this Article shall, at the option of the non assigning Party, be null and void and
                                         of no effect. No assignment shall release either Party from responsibility for the performance
                                         of any accrued obligation of such Party hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>15.5</B></FONT></TD><TD><FONT STYLE="color: Black"><B>Counterparts</B>. This Agreement
                                         may be executed in two copies, both of which shall be deemed to be originals, and both
                                         of which shall constitute one and the same Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>15.6</B></FONT></TD><TD><FONT STYLE="color: Black"><B>No Agency</B>. Nothing herein
                                         contained shall be deemed to create an agency, joint venture, amalgamation, partnership
                                         or similar relationship between Mallinckrodt and BI. Notwithstanding any of the provisions
                                         of this Agreement, neither Party shall at any time enter into, incur, or hold itself
                                         out to Third Parties as having authority to enter into or incur, on behalf of the other
                                         Party, any commitment, expense, or liability whatsoever, and all contracts, expenses
                                         and liabilities undertaken or incurred by one Party in connection with or relating to
                                         the Development, manufacture or Commercialization of Compound or Product shall be undertaken,
                                         incurred or paid exclusively by that Party, and not as an agent or representative of
                                         the other Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>15.7</B></FONT></TD><TD><FONT STYLE="color: Black"><B>Notice</B>. All communications
                                         between the Parties with respect to any of the provisions of this Agreement will be sent
                                         to the addresses set out below, or to other addresses as designated by one Party to the
                                         other by notice pursuant hereto, by internationally recognized courier or by prepaid
                                         certified, air mail (which shall be deemed received by the other Party on the seventh
                                         day following deposit in the mails), or by facsimile transmission or other electronic
                                         means of communication (which shall be deemed received when transmitted), with confirmation
                                         by letter given by the close of business on or before the next following day:</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">If to Mallinckrodt,
at:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><FONT STYLE="font-weight: normal; color: Black">Mallinckrodt
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">675 McDonnell Blvd</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">St. Louis, MO 63042</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">Attn: President,
Imaging Solutions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; color: Black">With
a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><FONT STYLE="font-weight: normal; color: Black">Mallinckrodt
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">675 McDonnell Blvd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">St. Louis, MO 63042</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><FONT STYLE="font-weight: normal; color: Black">Attn:
Vice President, Chief Corporate Counsel, Imaging Solutions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">If to BI at:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">Jack L. Erion</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><FONT STYLE="font-weight: normal; color: Black">President
&amp; CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 63pt"><FONT STYLE="font-weight: normal; color: Black">BioSynthema
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">4041 Forest Park
Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">St. Louis, MO 63108</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">Attn: President,
BioSynthema</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="color: Black">With a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">BioSynthema Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">Mary A. Palank, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">Vice President &amp;
General Counsel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">BioSynthema Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">Palank &amp; Associates
LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">1034 S. Brentwood
Blvd., Suite 1630</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">St. Louis, Missouri
63117</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>15.8</B></FONT></TD><TD><FONT STYLE="color: Black"><B>Survival</B>. Except where
                                         explicitly provided elsewhere herein, termination of this Agreement for any reason, or
                                         expiration of this Agreement, will not affect: (i) obligations, including the payment
                                         of any sums which have accrued as of the date of termination or expiration, and (ii)
                                         rights and obligations which, from the context thereof, are intended to survive termination
                                         or expiration of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>15.9</B></FONT></TD><TD><FONT STYLE="color: Black"><B>Headings</B>. The paragraph
                                         headings are for convenience only and will not be deemed to affect in any way the language
                                         of the provisions to which they refer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black"><B>15.10</B></FONT></TD><TD><FONT STYLE="color: Black"><B>Entire Agreement</B>. This
                                         Agreement together with its Exhibits shall supersede any prior agreement between the
                                         Parties and constitutes the entire understanding of the Parties relating to the matters
                                         referred to herein, and may only be amended by a written document, duly executed on behalf
                                         of the respective Parties. However the terms of this Agreement shall prevail over any
                                         conflicting terms contained in any of the Exhibits.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="color: Black"><B>15.11</B></FONT></TD><TD><FONT STYLE="color: Black"><B>Interpretation</B>. &nbsp;In this
Agreement unless the context requires otherwise:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="color: Black">(a)</FONT></TD><TD><FONT STYLE="color: Black">the singular includes the plural
and vice versa;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">&nbsp;</TD><TD><FONT STYLE="color: Black">&nbsp;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="color: Black">(b)</FONT></TD><TD><FONT STYLE="color: Black">a gender includes the other
genders;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(c)</FONT></TD><TD><FONT STYLE="color: Black">a reference to a document includes
                                         the document as modified from time to time and any document replacing it;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(d)</FONT></TD><TD><FONT STYLE="color: Black">if something is to be done on a
                                         day which is not a Business Day then that thing must be done on the next or following
                                         Business Day;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(e)</FONT></TD><TD><FONT STYLE="color: Black">&quot;month&quot; means calendar
                                         month and &quot;year&quot; means 12&nbsp;months;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(f)</FONT></TD><TD><FONT STYLE="color: Black">&quot;in writing&quot; includes
                                         any communication sent by letter, facsimile transmission or email;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(g)</FONT></TD><TD><FONT STYLE="color: Black">a reference to any statute, proclamation,
                                         rule, regulation or ordinance includes any amendment, consolidation, modification, re-enactment
                                         or reprint of it or any statute, proclamation, rule, regulation or ordinance replacing
                                         it. A reference to a specified section, clause, paragraph, schedule or item of any statute,
                                         proclamation, rule, regulation or ordinance means a reference to the equivalent section
                                         of the statute, proclamation, rule, regulation or ordinance which is for the time being
                                         in force;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(h)</FONT></TD><TD><FONT STYLE="color: Black">&quot;including&quot; and similar
                                         expressions are not words of limitation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(h)</FONT></TD><TD><FONT STYLE="color: Black">a reference to any agency or body,
                                         if that agency or body ceases to exist or is reconstituted, renamed or replaced or has
                                         its powers or functions removed (defunct body), means the agency or body which performs
                                         most closely the functions of the defunct body.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">ARTICLE 16</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">PAYMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">All payments due
to a Party hereunder shall be invoiced to the other Party within sixty (60) days following the Calendar Quarter that such payment
is due and owing, and the invoiced Party shall pay all undisputed invoices within sixty (60) days of the date of invoice by wire
transfer pursuant to the instructions on the invoicing Party&rsquo;s invoice statement. All payments due by either Party under
this Agreement, if not received as specified in this Agreement, shall accrue Interest until all such payments and Interest are
paid.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">ARTICLE 17</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">SALES AND USE
TAX</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">The payments hereunder
exclude any sales and use or similar taxes imposed by any state or local government in the US which taxes, if any, Mallinckrodt
will bear. BI agrees to collect and remit any such tax, if required to do so under the laws of any state or local jurisdictions.
Each Party shall cooperate with the other Party and take any action reasonably requested (which does not cause such Party to incur
any material cost or inconvenience) in order to minimize any taxes payable, including providing sales and use tax exemption certificates
or other documentation necessary to support sales or use tax exemptions. Mallinckrodt and BI agree to provide each other information
and data that they may from time to time reasonably request and otherwise fully cooperate with each other in connection with (i)
the reporting of any sales or use taxes payable; (ii) any sales or use tax audit; and (iii) any assessment, refund claim or proceeding
relating to taxes payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">ARTICLE 18</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">DISPUTE RESOLUTION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">If either Party
disagrees with the other Party regarding the adequacy of performance of a Party&rsquo;s obligations or any payments owing hereunder,
then the Parties agree to meet and negotiate such matter(s) in good faith toward a mutually acceptable resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>IN WITNESS WHEREOF</B>, the Parties
hereto have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">Mallinckrodt
    Inc.</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 57%; font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%; font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">/s/
    Steven J. Hanley</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">Name:</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">Steven
    J. Hanley</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">Title:
    </FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">President,
    Imaging Solutions</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">BioSynthema
    Inc. </FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">/s/
    Jack L. Erion</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">Name:</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">Jack L.
    Erion</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">Title:</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">President
    and CEO</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; color: Black">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-weight: normal; color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: Black"><B>Annex A.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">Amending Provisions
from Termination of Commercialization Agreement and Amendment<BR>
 to License Agreement, dated March 12, 2010, between BioSynthema
Inc. (&ldquo;BI&rdquo;) and<BR>
 Mallinckrodt Inc. (&ldquo;Mallinckrodt&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Section 1.2.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">Except as expressly
provided herein, the terms of the Commercialization Agreement governing the exercise and effect of early termination shall continue
to apply in full force and effect. Without limiting the generality of the foregoing, the terms of Section 13.2(d) and 13.4(a)
of the Commercialization Agreement shall apply and govern as written (including without limitation the grant of the BI Early Termination
License and BI's corresponding [*] percent ([*]%) royalty obligation through January 1, 2020 as set forth therein). Further, the
following terms of the Commercialization Agreement shall be incorporated in their entirety as additional terms of the License
Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">1.2.1&nbsp;&nbsp;&nbsp;Section
14.1, (Payments), shall be the new Article 16 of the License Agreement, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">1.2.2&nbsp;&nbsp;&nbsp;Section
14.14(a), (Sales and Use Tax), shall be the new Article 17 of the License Agreement, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">1.2.3&nbsp;&nbsp;&nbsp;Section
14.18, (Dispute Resolution), shall be the new Article 18 of the License Agreement, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">1.2.4&nbsp;&nbsp;&nbsp;Section
11.2, (Permitted Disclosures), shall replace Section 9.3 of the License Agreement in its entirety. For clarification, the Parties
agree that BI may disclose all of the terms of the License Agreement to a Third Party for the purpose of seeking financial assistance
and investment subject to and in accordance with the terms, conditions and stipulations of new Section 11.2, of the License Agreement.
Except for disclosures expressly permitted under Article 9 of the License Agreement (e.g., disclosure for the purpose of seeking
financial assistance and investment), the terms of Article 10 of the License Agreement require that both Parties must agree prior
to any disclosure to any Third Party, including press releases, concerning the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Section 2.2.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">The following provisions
of the License Agreement are hereby amended as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">2.2.1&nbsp;&nbsp;&nbsp;Articles
1, 2 and 4 of the License Agreement shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">2.2.2&nbsp;&nbsp;&nbsp;Article
3 of the License Agreement is hereby deleted in its entirety and replaced with the following: &quot;BioSynthema shall utilize
Commercially Reasonable Efforts to Develop and Commercialize the Product.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="color: Black">Certain confidential
information has been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been
filed on a confidential basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">2.2.3&nbsp;&nbsp;&nbsp;Article
5, Sections 5.1 through 5.4 (a), (b) and (c) of the License Agreement are hereby deleted in their entirety. Sections 5.5 and 5.6
shall survive and govern as written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">2.2.4&nbsp;&nbsp;&nbsp;New Section
5.4(b) of the License Agreement shall read in its entirety: &ldquo;Royalties shall be payable within sixty (60) days of the end
of each Calendar Quarter from the First Commercial Sale of the Product until 2020. Notwithstanding the foregoing, the royalties
hereunder shall cease to be payable in a country to the extent that the Mallinckrodt Patents are held to be invalid by a court
of competent jurisdiction in that country.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">2.2.5&nbsp;&nbsp;&nbsp;Article
6 of the License Agreement is hereby deleted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">2.2.6&nbsp;&nbsp;&nbsp;Articles
7 and 8 of the License Agreement shall survive and govern as written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">2.2.7&nbsp;&nbsp;&nbsp;Articles
10 through 15 of the License Agreement along with all exhibits shall remain in full force and effect as written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">2.2.8&nbsp;&nbsp;&nbsp;Section
1.55 of the License Agreement, (Royalty Term) shall be deleted in its entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">2.2.9&nbsp;&nbsp;&nbsp;Section
11.1 of the License Agreement (Term) shall be deleted in its entirety and shall be replaced as follows: &ldquo;11.1 Term. Unless
otherwise terminated as provided under this Article 11 or under Section 15.2 (Force Majeure), the term of the Agreement shall
commence as of the Effective Date and shall remain in full force and effect through January 1, 2020 (&ldquo;Term&rdquo;).&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black"><B>Section 3</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">Except as otherwise
provided for in this Termination and Amendment, the terms and conditions of the License Agreement remains in full force and effect.
To the extent that any of the terms of the License Agreement vary or conflict in any respect with the terms of this Termination
and Amendment, then the terms of this Termination and Amendment shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: Black"><B>Annex A.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>Relevant Provisions
of Commercialization Agreement dated February 5, 2008,<BR>
 between Mallinckrodt Inc. and BioSynthema Inc., incorporated into License
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Section 11.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black"><B>Permitted Disclosures</B>.
Each Party may disclose the Confidential Information to the extent such disclosure is reasonably necessary in filing or prosecuting
patent applications, prosecuting or defending litigation, or complying with any applicable statute or governmental regulation
provided such Party has given the disclosing Party prompt written notice allowing it to limit such disclosure. In addition, either
Party may disclose Confidential Information to its Affiliates and to its Sublicensees; provided, however, in connection with any
such disclosure the disclosing Party shall secure the same obligations of confidential treatment of such Confidential Information,
as required in this Article 11. BI may disclose all the terms of this Agreement and the License Agreement to a Third Party for
the purpose of seeking financial assistance and investment, and shall obligate such Third Parties to treat such information as
Confidential in accordance with this Article 11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Section 13.2(d)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black"><B>Termination Without
Cause</B>. Either Party may terminate this Agreement without cause upon twelve (12) months prior written notice to the other Party.
BI may exercise such right only if BI (i) warrants to Mallinckrodt in writing that BI shall discontinue all manufacturing of the
Compound, the Product Components, and the Product, whether for Mallinckrodt or otherwise, and (ii) agrees in writing to terminate
all of the rights of BI under the License Agreement. MI may exercise such right only if Mallinckrodt warrants to BI that, it shall
discontinue all marketing and sales of the Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Section 13.4(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black"><B>Termination by
Mallinckrodt</B>. Upon early termination of this Agreement by Mallinckrodt pursuant to Section 13.2(d) (Termination Without Cause),
the License Agreement shall nonetheless remain in full force and effect, BI shall automatically be granted the BI Early Termination
License and all obligations of BI to pay Mallinckrodt Milestones and Royalties as set forth in Article 5 of the License Agreement
shall be irrevocably waived. The royalty rate payable by BI for the BI Early Termination License under this paragraph (a) shall
be as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">(A) &#9;&nbsp;&nbsp;&nbsp;&nbsp;[*] percent ([*]%) of the annual
Net Sales of the Product to be paid in accordance with the terms of Section 14.1 for the stated Term of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="color: Black">Certain confidential
information has been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been
filed on a confidential basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: Black"><B>Annex A.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Section 14.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">Payments. All payments
due to a Party hereunder shall be invoiced to the other Party within sixty (60) days following the Calendar Quarter that such
payment is due and owing, and the invoiced Party shall pay all undisputed invoices within sixty (60) days of the date of invoice
by wire transfer pursuant to the instructions on the invoicing Party&rsquo;s invoice statement. All payments due by either Party
under this Agreement, if not received as specified in this Agreement, shall accrue Interest until all such payments and Interest
are paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">All royalty payments
owing for the sale of Products (as contemplated in Sections 4.8(b), 5.1(b), 5.4, 13.3 and 13.4), whether owing during the Term,
or to be paid after termination of this Agreement, shall be paid (without invoice or notice) by wire transfer by the Party owing
such royalty within sixty (60) days following the Calendar Quarter in which the sales generating such royalty payment occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">All payments, including
any late payment as set forth in this Section 14.1, shall be made in U.S. Dollars. The U.S. Dollar equivalent of Net Sales invoiced
in a currency other than U.S. Dollars shall be calculated in the same manner and using the same exchange rate as Mallinckrodt&rsquo;s
ultimate parent company (Covidien) uses to translate its consolidated income statements into U.S. Dollars. The methodology employed
by Covidien to translate its consolidated income statements into U.S. Dollars shall be in accordance with Accounting Standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Section 14.14(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">Sales and Use Tax.
The payments hereunder exclude any sales and use or similar taxes imposed by any state or local government in the US which taxes,
if any, Mallinckrodt will bear. BI agrees to collect and remit any such tax, if required to do so under the laws of any state
or local jurisdictions. Each Party shall cooperate with the other Party and take any action reasonably requested (which does not
cause such Party to incur any material cost or inconvenience) in order to minimize any taxes payable, including providing sales
and use tax exemption certificates or other documentation necessary to support sales or use tax exemptions. Mallinckrodt and BI
agree to provide each other information and data that they may from time to time reasonably request and otherwise fully cooperate
with each other in connection with (i) the reporting of any sales or use taxes payable; (ii) any sales or use tax audit; and (iii)
any assessment, refund claim or proceeding relating to taxes payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Section 14.18</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">If either Party
disagrees with the other Party regarding the adequacy of performance of a Party&rsquo;s obligations or any payments owing hereunder,
then the Parties agree to meet and negotiate such matter(s) in good faith toward a mutually acceptable resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
